PHP35 - AMNOG EARLY BENEFIT ASSESSMENT (EBA) AND MARKET PENETRATION OF NEW DRUGS FOR MELANOMA, MULTIPLE SCLEROSIS AND DIABETES MELLITUS IN GERMANY
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.931
https://www.valueinhealthjournal.com/article/S1098-3015(18)34233-5/fulltext
Title :
PHP35 - AMNOG EARLY BENEFIT ASSESSMENT (EBA) AND MARKET PENETRATION OF NEW DRUGS FOR MELANOMA, MULTIPLE SCLEROSIS AND DIABETES MELLITUS IN GERMANY
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)34233-5&doi=10.1016/j.jval.2018.09.931
First page :
Section Title :
Open access? :
No
Section Order :
320